Novoste Sees Guidant Pressure On Brachytherapy Market Abating In 2003
This article was originally published in The Gray Sheet
The price erosion for Novoste's Beta-Cath vascular brachytherapy (VBT) device that followed Guidant's aggressive promotion of the competing Galileo system should subside in 2003, according to Novoste
You may also be interested in...
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.